SCOTTSDALE, AZ -- (MARKET WIRE) -- January 24, 2007 -- Medistem Laboratories, Inc. (OTCBB: MDSM) (FRANKFURT: S2U), announced today it has filed a patent application covering its Angiostem™ platform, a technology with potential to benefit cardiac and limb ischemic diseases. Angiostem™ is planned to be the company's first pipeline product intended for U.S. commercialization.
